BioLife Solutions' CFO Sells 30,000 Shares

This bioproduction tools supplier for compartment and cistron therapy reported a notable insider merchantability amid a modestly downtrending stock price.

Troy Wichterman, Chief Financial Officer of BioLife Solutions (NASDAQ:BLFS), straight sold 30,000 shares connected Dec. 4, for a transaction worth of astir $771,600, according to the SEC Form 4 filing.

Transaction worth based connected SEC Form 4 weighted mean merchantability terms ($25.72); post-transaction worth based connected Dec. 4 marketplace adjacent of $25.83 (price not specified successful filing).

• How does the size of this transaction comparison to Wichterman's erstwhile selling activity?
  This 30,000-share merchantability is the largest azygous merchantability lawsuit successful Wichterman's reported history, exceeding the anterior maximum of 25,687 shares and acold supra the caller play median of 855 shares per sell.

• What information of Wichterman's nonstop holdings was sold, and however does this subordinate to his remaining capacity?
  The transaction accounted for 16.4% of his nonstop ownership, leaving him with 152,769 shares, which is astir 60.5% of his holdings astatine the commencement of the astir caller reporting period.

• Did the transaction impact immoderate indirect holdings, gifts, oregon derivative exercises?
  No indirect holdings, gifts, oregon enactment exercises were reported; the full transaction progressive a nonstop open-market merchantability of communal stock.

• What is the marketplace discourse for this transaction successful presumption of stock terms and institution performance?
  Shares were sold astatine a weighted mean terms of $25.72, with the marketplace closing astatine $25.83 connected Dec. 4; the banal had declined 2.1% implicit the trailing twelvemonth arsenic of the transaction date,.

Note: 1-year show is calculated utilizing Dec. 4 adjacent arsenic the notation date.

BioLife Solutions is simply a specialized supplier of bioproduction tools and services supporting the fast-growing compartment and cistron therapy sector. The institution leverages proprietary preservation and logistics technologies to code captious needs successful the manufacturing and organisation of precocious biologics. Its integrated portfolio and planetary scope presumption it arsenic a cardinal spouse for organizations processing and commercializing next-generation therapies.